Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Sponsor: Alliance for Clinical Trials in Oncology
A PHASE1 clinical study on Lymphoma, this trial is completed. The trial is conducted by Alliance for Clinical Trials in Oncology and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Feb 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .